Lead Product(s): Panobinostat lactate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 18, 2020
The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.